Literature DB >> 19857454

A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.

Emmalene J Bartlett1, Ann-Marie Cruz, Jim Boonyaratanakornkit, Janice Esker, Adam Castaño, Mario H Skiadopoulos, Peter L Collins, Brian R Murphy, Alexander C Schmidt.   

Abstract

A novel recombinant human parainfluenza virus type 1 (rHPIV1), rHPIV1-C+P, in which the overlapping open reading frames of the C and P genes were separated in order to introduce mutations into the C gene without affecting P, was generated. Infectious rHPIV1-C+P was readily recovered and replicated as efficiently as HPIV1 wild type (wt) in vitro and in African green monkeys (AGMs). rHPIV1-C+P expressed increased levels of C protein and, surprisingly, activated the type I IFN and apoptosis responses more strongly than HPIV1 wt. rHPIV1-C+P provided a useful backbone for recovering an attenuated P/C gene mutation (Delta 84-85), which was previously unrecoverable, likely due to detrimental effects of the deletion on the P protein. rHPIV1-C(Delta 84-85)+P and an additional mutant, rHPIV1-C(Delta 169-170)+P, were found to replicate to similar titers in vitro and to activate the type I IFN and apoptosis responses to a similar degree as rHPIV1-C+P. rHPIV1-C(Delta 84-85)+P was found to be highly attenuated in AGMs, and all viruses were immunogenic and effective in protecting AGMs against challenge with HPIV1 wt. rHPIV1-C(Delta 84-85)+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857454      PMCID: PMC2791187          DOI: 10.1016/j.vaccine.2009.10.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  57 in total

1.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Authors:  Ruth A Karron; Robert B Belshe; Peter F Wright; Bhagvanji Thumar; Barbars Burns; Frances Newman; Joan C Cannon; Juliette Thompson; Theodore Tsai; Maribel Paschalis; Shin-Lu Wu; Yvonne Mitcho; Jill Hackell; Brian R Murphy; Joanna M Tatem
Journal:  Pediatr Infect Dis J       Date:  2003-05       Impact factor: 2.129

3.  Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children.

Authors:  Marika K Iwane; Kathryn M Edwards; Peter G Szilagyi; Frances J Walker; Marie R Griffin; Geoffrey A Weinberg; Charmaine Coulen; Katherine A Poehling; Laura P Shone; Sharon Balter; Caroline B Hall; Dean D Erdman; Karen Wooten; Benjamin Schwartz
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

4.  Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Authors:  Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

5.  Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1.

Authors:  Judith A Smith; Matthew J Turner; Monica L DeLay; Erin I Klenk; Dawn P Sowders; Robert A Colbert
Journal:  Eur J Immunol       Date:  2008-05       Impact factor: 5.532

6.  Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Authors:  Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt
Journal:  Vaccine       Date:  2007-07-03       Impact factor: 3.641

7.  Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Authors:  Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis.

Authors:  Guruprasad R Medigeshi; Alissa M Lancaster; Alec J Hirsch; Thomas Briese; W Ian Lipkin; Victor Defilippis; Klaus Früh; Peter W Mason; Janko Nikolich-Zugich; Jay A Nelson
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

9.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

10.  Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.

Authors:  Emmalene J Bartlett; Adam Castaño; Sonja R Surman; Peter L Collins; Mario H Skiadopoulos; Brian R Murphy
Journal:  Virol J       Date:  2007-07-02       Impact factor: 4.099

View more
  6 in total

Review 1.  Progress in the development of human parainfluenza virus vaccines.

Authors:  Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins
Journal:  Expert Rev Respir Med       Date:  2011-08       Impact factor: 3.772

Review 2.  Type I and Type II Interferon Antagonism Strategies Used by Paramyxoviridae: Previous and New Discoveries, in Comparison.

Authors:  Giuseppe Pisanelli; Ugo Pagnini; Giuseppe Iovane; Adolfo García-Sastre
Journal:  Viruses       Date:  2022-05-21       Impact factor: 5.818

3.  Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.

Authors:  Natalie Mackow; Emérito Amaro-Carambot; Bo Liang; Sonja Surman; Matthias Lingemann; Lijuan Yang; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

4.  Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.

Authors:  Anne Schaap-Nutt; Rachael Liesman; Emmalene J Bartlett; Margaret A Scull; Peter L Collins; Raymond J Pickles; Alexander C Schmidt
Journal:  Virology       Date:  2012-09-07       Impact factor: 3.616

Review 5.  Review detection of Newcastle disease virus.

Authors:  Qian Mao; Shengming Ma; Philip Luke Schrickel; Pengwei Zhao; Jingya Wang; Yuhua Zhang; Shuangyu Li; Chengbao Wang
Journal:  Front Vet Sci       Date:  2022-08-02

Review 6.  C Proteins: Controllers of Orderly Paramyxovirus Replication and of the Innate Immune Response.

Authors:  Oliver Siering; Roberto Cattaneo; Christian K Pfaller
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.